Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + Pemigatinib in PD-L1+ FGFR-mutated NSCLC
NCT05004974Phase 2Recruiting
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2022
- Primary completion
- Sep 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, pemigatinib in non-small cell lung cancer (NSCLC), sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Started Apr 2022; status: recruiting.
02
Drugs
sintilimabpemigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05004974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05004974.